Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)
第3相
完了
NCT04662710
| 対象疾患 | Advanced/Metastatic Gastroesophageal Adenocarcinoma |
|---|
| 相 | 第3相 |
|---|
| スポンサー | Merck Sharp & Dohme LLC |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 895 名 |
|---|
| 介入（薬剤） | Pembrolizumab, Lenvatinib, Oxaliplatin, Capecitabine, Leucovorin (or Levoleucovorin) |
|---|
| 開始日 | 2020年12月30日 |
|---|
| 完了日 | 2024年10月29日 |
|---|
| 結果公開日 | 2025年11月28日 |
|---|
概要
The purpose of this study is to assess the efficacy and safety of lenvatinib (E7080/MK-7902) plus pembrolizumab (MK-3475) plus chemotherapy compared with chemotherapy alone in participants with advanced/metastatic gastroesophageal cancer. The primary study hypotheses are that lenvatinib plus pembrolizumab plus chemotherapy is superior to chemotherapy alone for both overall survival (OS) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR), in participants with programmed cell death-ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 and in all participants.
Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)
Up to ~21 days · Participants
| Part 1 : Lenvatinib + Pembrolizumab + Chemotherapy | 2 Participants |
|---|
Part 1: Number of Participants With Adverse Events (AEs)
Up to ~44 months · Participants
| Safety Run-In: Lenvatinib + Pembrolizumab + Chemotherapy | 15 Participants |
|---|
Part 1: Number of Participants Who Discontinued Study Treatment Due to an AE
Up to ~29 months · Participants
| Safety Run-In: Lenvatinib + Pembrolizumab + Chemotherapy | 5 Participants |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。